Krystal Biotech (NASDAQ:KRYS) Trading 6.3% Higher

Shares of Krystal Biotech Inc (NASDAQ:KRYS) traded up 6.3% during mid-day trading on Friday . The company traded as high as $55.35 and last traded at $54.43, 178,400 shares traded hands during trading. An increase of 23% from the average session volume of 145,449 shares. The stock had previously closed at $51.21.

A number of equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a research report on Tuesday, September 24th. They set a “neutral” rating and a $60.00 price target for the company. Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research report on Tuesday, November 5th. Guggenheim set a $81.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a research report on Thursday, September 26th. Finally, ValuEngine upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $59.33.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 54.87 and a current ratio of 54.87. The stock has a market capitalization of $933.27 million, a price-to-earnings ratio of -56.11 and a beta of 1.03. The company has a 50-day moving average of $41.82 and a 200-day moving average of $40.43.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.14. As a group, analysts expect that Krystal Biotech Inc will post -1.25 earnings per share for the current year.

In related news, CEO Krish S. Krishnan sold 27,879 shares of Krystal Biotech stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $50.41, for a total transaction of $1,405,380.39. Following the completion of the transaction, the chief executive officer now directly owns 2,024,567 shares in the company, valued at approximately $102,058,422.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Janney sold 88,684 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $46.46, for a total value of $4,120,258.64. Following the transaction, the director now owns 35,131 shares of the company’s stock, valued at $1,632,186.26. The disclosure for this sale can be found here. Insiders have sold a total of 138,684 shares of company stock valued at $6,683,231 over the last 90 days. Insiders own 34.30% of the company’s stock.

Several institutional investors have recently modified their holdings of KRYS. Price T Rowe Associates Inc. MD raised its position in shares of Krystal Biotech by 204.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 927,079 shares of the company’s stock worth $37,333,000 after purchasing an additional 622,959 shares during the last quarter. Orbimed Advisors LLC raised its holdings in Krystal Biotech by 984.3% in the 2nd quarter. Orbimed Advisors LLC now owns 642,006 shares of the company’s stock valued at $25,854,000 after acquiring an additional 582,796 shares during the last quarter. BlackRock Inc. raised its holdings in Krystal Biotech by 989.8% in the 2nd quarter. BlackRock Inc. now owns 601,514 shares of the company’s stock valued at $24,224,000 after acquiring an additional 546,317 shares during the last quarter. Citadel Advisors LLC raised its holdings in Krystal Biotech by 54.0% in the 2nd quarter. Citadel Advisors LLC now owns 497,170 shares of the company’s stock valued at $20,021,000 after acquiring an additional 174,296 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Krystal Biotech by 40.6% in the 2nd quarter. Vanguard Group Inc. now owns 496,879 shares of the company’s stock valued at $20,009,000 after acquiring an additional 143,409 shares during the last quarter. Hedge funds and other institutional investors own 58.00% of the company’s stock.

Krystal Biotech Company Profile (NASDAQ:KRYS)

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Recommended Story: Book Value Per Share – BVPS

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.